mAbs Purification
Monoclonal antibodies (mAbs) are biopharmaceuticals that can be used for treating a range of pathologies, including diabetes, infections and cancer, as well as cardiovascular and immune diseases.
Current industrial mAbs production through batch chromatography faces significant challenges from high purification costs, and also presents environmental concerns due to the extensive use of chemicals.
The Science that Drives BIOPURE
BIOPURE will provide breakthrough advancements in the purification of mAbs, away from batch chromatography to continuous crystallisation, by using modular and easily scalable membranes. These membranes allow for a viable new manufacturing process with greater efficiency and a reduction in facilities size, leading to lower capital and operating costs. The process is also more environmentally responsible, while still attaining the high purity and biostability achievable from conventional production methods.
Where we are headed
The BIOPURE membrane-based technology has been validated at laboratory-scale (TRL4) as a more cost-effective and easily scalable alternative to chromatography-based processes.
Our next step will be to demonstrate the efficiency of this technology by scaling it up to TRL6-level through a fully-automated prototype, operating continuously and meeting the levels of quality required under regulated biopharmaceutical production.